gMSC 1

Drug Profile

gMSC 1

Alternative Names: gMSC®1

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Two Cells
  • Class Stem cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cartilage disorders

Most Recent Events

  • 14 Jul 2017 Phase-III clinical trials in Cartilage disorders in Japan (Parenteral) (JapicCTI-173603)
  • 05 Jun 2017 Twocells company plans a phase III trial for Cartilage disorders in Japan (JapicCTI-173603)
  • 25 Apr 2016 Chugai Pharmaceutical in-licenses Synovium-derived mesenchymal stem cells from Two Cells for development in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top